Poly (ADP-ribose) Polymerase (PARP) inhibitors are promising novel radiosensitisers. Pre-clinical models have demonstrated potent and tumour-specific radiosensitisation by PARP inhibitors. | Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib